A Feasibility Study: Assessing Photobiomodulation in Myalgic Encephalomyelitis

Launched by QUADRAM INSTITUTE BIOSCIENCE · Nov 16, 2023

Keywords

ClinConnect Summary

The prevailing theory regarding mechanism of action of PBM is that by activating cytochrome c oxidase (CCO) it boosts mitochondrial ATP production, which, in turn, enhances the metabolic activity of the cell. This occurs simultaneously with the regulation of the reduction/oxidation (redox) state of the intracellular microenvironment favouring expression of genes associated with tissue regeneration and repair. Immune modulation and dampening or attenuation of pro-inflammatory responses ensures a coordinated regenerative effort. An alternate mechanism of action, independent of the absorption ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants who have received an ME diagnosis from primary or secondary care
• • must be able to understand the requirements of the study and provide informed consent.
• • must live in the UK
• Exclusion Criteria:
• • Participants who have received one or more of the following diagnoses: 1) any illness other than ME/CFS that has fatigue as a symptom (e.g. multiple sclerosis or inherited mitochondrial disease), 2) any illness with cognitive defects (e.g. alzheimer's disease, dementia), 3) any proliferative disease (e.g. cancer), 4) any surface bacterial/fungal infection (e.g. blepharitis)
• • Participants who have altered their medication within the last 4 weeks
• • Participants who have made major dietary alterations within the last 4 weeks
• • Participants who have underwent surgery requiring general anaesthetic within the last 6 months
• • Participants who have broken/fractured/torn any bones or ligaments within the last 6 months
• • Participants who are pregnant